Pharmacologic management of psychiatric and behavioral symptoms in mental retardation.
Compared with the general population, individuals with mental retardation demonstrate more susceptibility to psychiatric illness and may display disruptive behaviors. These symptoms significantly can affect an already compromised ability to function and the patient may benefit from pharmacologic intervention. Clinical characteristics of individuals with mental retardation warrant special consideration regarding diagnosis and treatment of their psychiatric and behavioral problems. This article describes the nature of symptoms that are typically the target of pharmacologic intervention, outlines special diagnostic considerations, and examines recent findings and experience with psychotropic medication in mental retardation.
Madrid
A L
AL
Department of Child and Adolescent Psychiatry, Yale Child Study Center, Yale University School of Medicine, New Haven, Connecticut, USA.
State
M W
MW
King
B H
BH
D000293:Adolescent; D002648:Child; D002653:Child Behavior Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D002986:Clinical Trials as Topic; D015897:Comorbidity; D004359:Drug Therapy, Combination; D006801:Humans; D008607:Intellectual Disability / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D001523:Mental Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D011619:Psychotropic Drugs